New Competition Brings Innovation to Diabetes Management

A new competition to bring innovation into the daily lives of type 2 diabetes patients was launched on April 10.

The Alexa Diabetes Challenge is calling on innovators to create Alexa voice-enabled solutions to improve the lives of those with type 2 diabetes. The $250,000, multi-stage, prize competition is sponsored by Merck & Co., and supported by Amazon Web Services (AWS). The Challenge is powered by Luminary Labs.

An estimated 27.5 million people live with type 2 diabetes in the U.S. Thanks to greater awareness and better treatments, many who have been diagnosed with the disease are living longer, healthier lives. But diabetes requires changes and considerations that permeate throughout every aspect of life. The path to self-management can feel isolating and overwhelming, especially for those who have been newly diagnosed.

The Alexa Diabetes Challenge invites innovators to submit concepts that utilize the capabilities of Amazon Alexa and the ecosystem of supporting cloud technologies to improve the experience of those newly diagnosed with type 2 diabetes.

Up to five finalists will be chosen by a panel of judges with expertise across health tech innovation, Amazon voice technology, the diabetes experience, data and ethics, and healthcare funding. Each finalist will receive $25,000 and 10,000 AWS credits, and advance to the Virtual Accelerator, during which they will receive expert mentorship as they develop their concepts into solutions. In addition, AWS will host an Innovators’ Boot Camp for the finalists at Amazon’s Seattle headquarters. At the end of the Virtual Accelerator, finalists will present their solutions in-person to the judges at Demo Day at the AWS Pop-up loft in New York City. Following Demo Day, the judges will select a winner, who will receive the $125,000 grand prize.

Interested in entering? Submit at by 5:00 PM ET on May 22, 2017.

You may also like

  • Liraglutide Increases Insulin Sensitivity Independent of Weight Loss, Study Shows

    Liraglutide, the glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat type 2 diabetes and obesity, can lead to rapid improvement in insulin sensitivity, according to a study recently published in Diabetes. “We know that GLP-1R agonists promote weight loss, but we were surprised to find that the GLP-1R agonist liraglutide also has rapid effects on…

  • COVID-19 Vaccines and Hyperglycemia in Patients with Type 1 Diabetes

    While proven to be safe, the COVID-19 vaccines could cause some people with type 1 diabetes to see their blood sugar to temporarily spike. The key for both patient and provider is to remain vigilant with glucose testing and insulin dosing post-jab to maintain glycemic control.  In the summer of 2021, a 24-year-old woman presented…